• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer and Clinical Oncology >Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston AS2-1 in Combination with Targeted Therapy
【24h】

Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston AS2-1 in Combination with Targeted Therapy

机译：联合抗肿瘤药AS2-1联合靶向治疗多形性胶质母细胞瘤（rGBM）

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Treatment of recurrent glioblastoma multiforme (rGBM) poses a difficult challenge. Therefore, the purpose of this report was to evaluate objective response (OR), progression-free survival (PFS), overall survival (OS), and the incidence of adverse events (AEs) in rGBM patients, age 19-70 years, who were treated with antineoplaston AS2-1 (Astugenal) plus targeted therapy. A retrospective analysis was performed. Tumor response was assessed by gadolinium-enhanced magnetic resonance imaging (MRI). Twenty-nine adult rGBM patients were treated between 9/11/2015 and 06/23/2018. Seven had no prior treatment with bevacizumab elsewhere, had radiologic evidence of rGBM, and had MRI assessment of tumor response. The median treatment time was 101 days (range: 55-208 days). OR was seen in six patients (85.7%) with complete disappearance of gadolinium enhancement in four patients (57.1%) and a 50% or greater reduction in gadolinium enhancement in two patients (28.6%). Progressive disease was seen in one patient (14.3%). The median time to first response was 29 days (range: 22-96 days) while the median duration of response was 141 days (range 55-739+ days). Six- and 12-month PFS was 57% and 19%, respectively while 6- and 12-month OS at was 86% and 54%, respectively. Treatment was well-tolerated with no patients experiencing grade 3 or 4 antineoplaston-related toxicity. Regarding response to treatment and toxicity, AS2-1 plus targeted therapy compares favorably with other reported rGBM therapies. Duration of response was shortened by the ill-advised decision of some patients to discontinue treatment after a tumor response was achieved.
机译：复发性多形性胶质母细胞瘤（rGBM）的治疗提出了一个艰巨的挑战。因此，本报告的目的是评估年龄在19-70岁的rGBM患者的客观反应（OR），无进展生存期（PFS），总生存期（OS）和不良事件的发生率（AEs）。接受抗血管生成素AS2-1（Astugenal）联合靶向治疗。进行回顾性分析。通过g增强磁共振成像（MRI）评估肿瘤反应。在2015年11月11日至2018年6月23日之间治疗了29名成人rGBM患者。 7名患者未曾在其他地方接受过贝伐单抗的先前治疗，具有rGBM的放射学证据，并进行了肿瘤反应的MRI评估。中位治疗时间为101天（范围：55-208天）。六名患者（85.7％）观察到OR，其中四名患者（57.1％）的enhancement增强完全消失，两名患者（28.6％）的enhancement增强降低了50％或更多。在一名患者中观察到了进行性疾病（14.3％）。首次反应的中位时间为29天（范围：22-96天），而反应的中位时间为141天（范围为55-739 +天）。六个月和十二个月的PFS分别为57％和19％，而六个月和十二个月的OS分别为86％和54％。治疗耐受性良好，没有患者发生3级或4级抗肿瘤生长激素相关毒性。关于治疗和毒性反应，AS2-1加靶向治疗与其他已报道的rGBM治疗相比具有优势。由于某些患者在达成肿瘤反应后不明智的决定中止治疗，从而缩短了反应时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号